Vital Signs: Prevalence of Key Cardiovascular Disease Risk Factors for Million Hearts 2022-United States, 2011-2016

被引:79
|
作者
Wall, Hilary K. [1 ]
Ritchey, Matthew D. [1 ]
Gillespie, Cathleen [1 ]
Omura, John D. [2 ]
Jamal, Ahmed [3 ]
George, Mary G. [1 ]
机构
[1] CDC, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA
[2] CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA
[3] CDC, Off Smoking & Hlth, Atlanta, GA 30333 USA
来源
关键词
UNITED-STATES; MORTALITY;
D O I
10.15585/mmwr.mm6735a4
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction: Despite decades-long reductions in cardiovascular disease (CVD) mortality, CVD mortality rates have recently plateaued and even increased in some subgroups, and the prevalence of CVD risk factors remains high. Million Hearts 2022, a 5-year initiative, was launched in 2017 to address this burden. This report establishes a baseline for the CVD risk factors targeted for reduction by the initiative during 2017-2021 and highlights recent changes over time. Methods: Risk factor prevalence among U.S. adults was assessed using data from the National Health and Nutrition Examination Survey, National Survey on Drug Use and Health, and National Health Interview Survey. Multivariate analyses were performed to assess differences in prevalence during 2011-2012 and the most recent cycle of available data, and across subgroups Results: During 2013-2014, the prevalences of aspirin use for primary and secondary CVD prevention were 27.4% and 74.9%, respectively, and of statin use for cholesterol management was 54.5%. During 2015-2016, the average daily sodium intake was 3,535 mg/day and the prevalences of blood pressure control, combustible tobacco use, and physical inactivity were 48.5%, 22.3%, and 29.1%, respectively. Compared with 2011-2012, significant decreases occurred in the prevalences of combustible tobacco use and physical inactivity; however, a decrease also occurred for aspirin use for primary or secondary prevention. Disparities in risk factor prevalences were observed across age groups, genders, and racial/ethnic groups. Conclusions and Implications for Public Health Practice: Millions of Americans have CVD risk factors that place them at increased risk for having a cardiovascular event, despite the existence of proven strategies for preventing or managing CVD risk factors. A concerted effort to implement these strategies will be needed to prevent one million acute cardiovascular events during the 5-year initiative.
引用
收藏
页码:983 / 991
页数:9
相关论文
共 50 条
  • [1] Citizenship status and the prevalence, treatment, and control of cardiovascular disease risk factors in United States, 2011-2016
    Guadamuz, Jenny S.
    Durazo-Arvizu, Ramon
    Daviglus, Martha L.
    Calip, Gregory S.
    Nutescu, Edith A.
    Qato, Dima M.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 159 - 160
  • [2] IS Citizenship Status and the Prevalence, Treatment, and Control of Cardiovascular Disease Risk Factors Among Immigrants in United States, 2011-2016
    Guadamuz, Jenny S.
    Durazo-Arvizu, Ramon A.
    Daviglus, Martha L.
    Calip, Gregory
    Nutescu, Edith
    Qato, Dima
    [J]. CIRCULATION, 2020, 141
  • [3] Citizenship Status and the Prevalence, Treatment, and Control of Cardiovascular Disease Risk Factors Among Adults in the United States, 2011-2016
    Guadamuz, Jenny S.
    Durazo-Arvizu, Ramon A.
    Daviglus, Martha L.
    Calip, Gregory S.
    Nutescu, Edith A.
    Qato, Dima M.
    [J]. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2020, 13 (03): : E006215
  • [4] Million Hearts: Prevalence of Leading Cardiovascular Disease Risk Factors - United States, 2005-2012
    Ritchey, Matthew D.
    Wall, Hilary K.
    Gillespie, Cathleen
    George, Mary G.
    Jamal, Ahmed
    [J]. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2014, 63 (21): : 462 - 467
  • [5] Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016
    Cheng, Yiling J.
    Kanaya, Alka M.
    Araneta, Maria Rosario G.
    Saydah, Sharon H.
    Kahn, Henry S.
    Gregg, Edward W.
    Fujimoto, Wilfred Y.
    Imperatore, Giuseppina
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (24): : 2389 - 2398
  • [6] Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016
    Hirode, Grishma
    Wong, Robert J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (24): : 2526 - 2528
  • [7] Million Hearts: Strategies to Reduce the Prevalence of Leading Cardiovascular Disease Risk Factors-United States, 2011 (Reprinted from MMWR, vol 60, pg 1248-1251, 2011)
    Valderrama, Amy L.
    Loustalot, Fleetwood
    Gillespie, Cathleen
    George, Mary G.
    Schooley, Michael
    Briss, Peter
    Dube, Shanta
    Jamal, Ahmed
    Yoon, Paula W.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (17): : 1854 - 1856
  • [8] Prevalence and distribution of high-risk prescription opioid use in the United States, 2011-2016
    McCormick, Carter D.
    Dadiomov, David
    Trotzky-Sirr, Rebecca
    Qato, Dima M.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (11) : 1532 - 1540
  • [9] Association Between Obesity, Cardiovascular Disease Risk Factors, and Parenthood: NHANES 2011-2016
    Neshteruk, Cody
    Norman, Katherine
    Armstrong, Sarah
    Skinner, Asheley
    [J]. OBESITY, 2020, 28 : 51 - 51
  • [10] Multidrug-resistant tuberculosis in the United States, 2011-2016: patient characteristics and risk factors
    Chen, M. P.
    Miramontes, R.
    Kammerer, J. S.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2020, 24 (01) : 92 - +